

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371</b>		ATTORNEY'S DOCKET NUMBER <b>05116/HG</b>
INTERNATIONAL APPLICATION NO. <b>PCT/JP2003/011004</b>	INTERNATIONAL FILING DATE <b>29 AUGUST 2003</b>	U.S. APPLICATION NO. (If known) See 37 CFR 1.5 <b>10/525986</b>
TITLE OF INVENTION <b>THERAPEUTIC AGENT FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDIN</b>		
APPLICANT(S) FOR DO/EO/US <b>Tadashi NAKAJIMA; Takeshi MATSUGI; and Hideaki HARA</b>		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> <li><input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a submission under 35 U.S.C. 371.</li> <li><input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a submission under 35 U.S.C. 371.</li> <li><input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</li> <li><input checked="" type="checkbox"/> The US has been elected (Article 31).</li> <li><input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))             <ol style="list-style-type: none"> <li><input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</li> <li><input checked="" type="checkbox"/> has been communicated by the International Bureau.</li> <li><input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ol> </li> <li><input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2))             <ol style="list-style-type: none"> <li><input checked="" type="checkbox"/> is attached hereto.</li> <li><input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</li> </ol> </li> <li><input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))             <ol style="list-style-type: none"> <li><input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</li> <li><input type="checkbox"/> have been communicated by the International Bureau.</li> <li><input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li><input type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li><input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li> <li><input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</li> <li><input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</li> </ol>		
Items 11 to 20 below concern document(s) or information included:		
<ol style="list-style-type: none"> <li><input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li><input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li><input checked="" type="checkbox"/> A preliminary amendment. which removes multiple dependent claims</li> <li><input type="checkbox"/> An Application Data Sheet under 37 CFR 1.76.</li> <li><input type="checkbox"/> A substitute specification.</li> <li><input checked="" type="checkbox"/> A power of attorney and/or change of address letter.</li> <li><input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825.</li> <li><input type="checkbox"/> A second copy of the published International Application under 35 U.S.C. 154(d)(4).</li> <li><input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</li> <li><input type="checkbox"/> Other items or information:</li> </ol>		

## Copy of:

- (i) NOTIFICATION PCT/IB/304
- (ii) NOTICE PCT/IB/308
- (iii) WO 2004/019951 A1 (title page only), the publication of PCT/JP2003/011004
- (iv) INT. PREL. EXAM. REPORT PCT/PEA/409
- (v) REQUEST FOR PUBLICATION OF ASSIGNMENT INFO  
2 sheets drawings (for the Examiner's convenience)

**Express Mail Label No. EV 620 174 069 US****Date of Deposit: February 25, 2005**

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above with sufficient postage, and is addressed to the Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450


  
Lori Valdes

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)		INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMBER											
<b>10/525986</b>		PCT/JP2003/011004		05116/HG											
21. The following fees are submitted:															
<input checked="" type="checkbox"/> a) Basic national fee.....		\$300.00		\$ 300.00											
<input checked="" type="checkbox"/> b) Examination fee.....		\$200.00		\$ 200.00											
<input checked="" type="checkbox"/> c) Search fee.....		\$500.00		\$ 500.00											
<b>TOTAL OF ABOVE CALCULATIONS =</b>			<b>\$1000.00</b>												
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.															
Total Sheets	Extra sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE	<table border="1" style="float: right; margin-right: 10px;"> <tr> <td>PEO VALUE</td> <td>ACCOUNTABILITY</td> </tr> <tr> <td>DEPOSIT ACCOUNT NO.</td> <td></td> </tr> <tr> <td>06</td> <td>1378</td> </tr> <tr> <td>PEO</td> <td>VALU</td> </tr> <tr> <td>00</td> <td>500</td> </tr> </table>		PEO VALUE	ACCOUNTABILITY	DEPOSIT ACCOUNT NO.		06	1378	PEO	VALU	00	500
PEO VALUE	ACCOUNTABILITY														
DEPOSIT ACCOUNT NO.															
06	1378														
PEO	VALU														
00	500														
- 100 =	/50 =		x \$250.00	\$											
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).															
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	1646 400										
Total claims	16	- 20 = 0	x \$50.00	\$	.00										
Independent claims	4	- 3 = 1	x \$200.00	\$	200.00										
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$360.00	\$	.00										
<b>TOTAL OF ABOVE CALCULATIONS =</b>			\$ 1.200.00	\$											
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.															
<b>SUBTOTAL = \$ 1.200.00</b>															
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).															
<b>TOTAL NATIONAL FEE = \$ 1.200.00</b>															
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property.															
<b>TOTAL FEES ENCLOSED = \$ 1.240.00</b>															
<table border="1" style="width: 100%;"> <tr> <td>Amount to be refunded:</td> <td>\$ .00</td> </tr> <tr> <td>Amount to be charged:</td> <td>\$ .00</td> </tr> </table>						Amount to be refunded:	\$ .00	Amount to be charged:	\$ .00						
Amount to be refunded:	\$ .00														
Amount to be charged:	\$ .00														
<p>a. <input type="checkbox"/> A check in the amount of \$ <u>1.240.00</u> to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>06-1378</u>. A duplicate copy of this sheet is enclosed.</p> <p>d. <input type="checkbox"/> Fees are to be charged to a credit card. <b>WARNING:</b> Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</p>															
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.															
SEND ALL CORRESPONDENCE TO:															
<b>CUSTOMER NO. 01933</b>															
Herbert Goodman Frishauf, Holtz, Goodman & Chick P.C. 767 Third Avenue 25 <sup>th</sup> Floor New York NY 10017-2023															
 <b>SIGNATURE</b> <b>Herbert Goodman</b> <b>NAME</b> <b>17,081</b> <b>REGISTRATION NUMBER</b>															

10,525986

DT06 Rec'd PCT/PTO 25 FEB 2005

PTO/SB/122 (10-00)

Please type a plus sign (+) inside this box → [+]

Approved for use through 10/31/2002. OMB 0651-0035

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**CHANGE OF  
CORRESPONDENCE ADDRESS**  
*Application*

**Address to:**  
**Commissioner for Patents**  
**P.O. Box 1450**  
**Alexandria, VA 22313-1450**

Application Number	
Filing Date	Concomitantly herewith
First Named Inventor	T. NAKAJIMA et al
Group Art Unit	
Examiner Name	
Attorney Docket Number	05116/HG

Please change the Correspondence Address for the above-identified application to:

Customer Number **[ 01933 ]**

**OR**

<input type="checkbox"/> Firm or Individual Name				
Address				
Address				
City		State	ZIP	
Country				
Telephone			Fax	

This form cannot be used to change the data associated with a Customer Number. To change the data associated with an existing Customer Number use "Request for Customer Number Data Change" (PTO/SB/124).

I am the:

Applicant/Inventor.

Assignee of record of the entire interest.  
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

Attorney or Agent of record.

Registered practitioner named in the application transmittal letter in an application without an executed oath or declaration. See 37 CFR 1.33(a)(1). Registration Number \_\_\_\_\_.

Typed or Printed

Name **Herbert Goodman, Reg. No. 17,081**

Signature



Date

February 25, 2005

**NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required.  
Submit multiple forms if more than one signature is required. See below.**

Total of **1** forms are submitted.

**Burden Hour Statement:** This form is estimated to take 3 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

10,525986

DTOS Rec'd PCT/PTO 25 FEB 2005

**IN THE UNITED STATES PATENT  
AND TRADEMARK OFFICE**

Appl. No. : (U.S. National Phase Appln.  
based on PCT/JP2003/011004)

Applicant : Tadashi NAKAJIMA et al

Filed : Concomitantly herewith

For : THERAPEUTIC AGENT FOR  
GLAUCOMA COMPRISING Rho  
KINASE INHIBITOR AND  
PROSTAGLANDIN

Docket No. : 05116/HG

Customer No.: 01933

Express Mail Mailing Label  
No.: EV 620 174 069 US  
Date of Deposit: February 25, 2005

I hereby certify that this paper is being  
deposited with the United States Postal  
Service "Express Mail Post Office to  
Addressee" service under 37 CFR 1.10 on the  
date indicated above and is addressed to  
the Commissioner for Patents, P.O. Box 1450,  
Alexandria, VA 22313-1450.

*Lori Valdes*  
Lori Valdes

In the event that this Paper is late filed,  
and the necessary petition for extension of  
time is not filed concurrently herewith,  
please consider this as a Petition for the  
requisite extension of time, and to the  
extent not tendered by check attached  
hereto, authorization to charge the  
extension fee, or any other fee  
required in connection with this Paper  
to Account No. 06-1378.

**REQUEST FOR PUBLICATION OF  
ASSIGNMENT INFORMATION**

COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, VA 22313-1450

S I R :

It is requested that the following assignment information be  
published as part of the 18 month publication of the present  
application:

SANTEN PHARMACEUTICAL CO., LTD.  
9-19, Shimoshinjo 3-chome, Higashiyodogawa-ku,  
Osaka-shi, Osaka 533-8651 Japan

Frishauf, Holtz, Goodman  
& Chick, P.C.  
767 Third Ave., 25th floor  
New York, NY 10017-2023  
Telephone: (212) 319-4900  
Facsimile: (212) 319-5101  
HG/lpv

Respectfully submitted,

*Herb Goodman*  
HERBERT GOODMAN  
Reg. No. 17,081